Mobile Tigecycline Resistance: An Emerging Health Catastrophe Requiring Urgent One Health Global Intervention

• Published in: Frontiers in microbiology Vol. 13; p. 808744
• Main Authors: Anyanwu, Madubuike Umunna, Nwobi, Obichukwu Chisom, Okpala, Charles Odilichukwu R., Ezeonu, Ifeoma M.
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 01.08.2022
• Subjects: antimicrobial resistance; health threat; Microbiology; mobile tigecycline resistance; One Health; tetracycline overuse; tetracycline overuse; antimicrobial resistance; mobile tigecycline resistance; health threat; One Health
• ISSN: 1664-302X; 1664-302X
• DOI: 10.3389/fmicb.2022.808744

Mobile tigecycline resistance (MTR) threatens the clinical efficacy of the salvage antibiotic, tigecycline (TIG) used in treating deadly infections in humans caused by superbugs (multidrug-, extensively drug-, and pandrug-resistant bacteria), including carbapenem- and colistin-resistant bacteria. Currently, non-mobile tet (X) and mobile plasmid-mediated transmissible tet (X) and resistance-nodulation-division (RND) efflux pump tmexCD-toprJ genes, conferring high-level TIG (HLT) resistance have been detected in humans, animals, and environmental ecosystems. Given the increasing rate of development and spread of plasmid-mediated resistance against the two last-resort antibiotics, colistin (COL) and TIG, there is a need to alert the global community on the emergence and spread of plasmid-mediated HLT resistance and the need for nations, especially developing countries, to increase their antimicrobial stewardship. Justifiably, MTR spread projects One Health ramifications and portends a monumental threat to global public and animal health, which could lead to outrageous health and economic impact due to limited options for therapy. To delve more into this very important subject matter, this current work will discuss why MTR is an emerging health catastrophe requiring urgent One Health global intervention, which has been constructed as follows: (a) antimicrobial activity of TIG; (b) mechanism of TIG resistance; (c) distribution, reservoirs, and traits of MTR gene-harboring isolates; (d) causes of MTR development; (e) possible MTR gene transfer mode and One Health implication; and (f) MTR spread and mitigating strategies.